expertise, études et conseils dans des organisations, cabinets ou sociétés fournissant des prestations intellectuelles, des expertises scientifiques, prospectives ou stratégiques*
Coordonnées
22 rue Hermel 75018 PARIS 18E ARRONDISSEMENT
Techniques maîtrisées
Microsoft Word, Microsoft PowerPoint, Microsoft Excel, Basic SQL, Visio
Expertise: Business Development, Consulting, International Relations, Communications, Healthcare, Market Access, Specialty Pharmaceuticals, Tech Solutions, Biotech
Compétences
Primary & Secondary Research, Business Development, Consulting, Communications, Strategic Planning, Problem-Solving, Negotiation & Collaboration, Critical Analysis, Strategizing, Pressure-Testing Simulations
Doctorat
Intitulé : Biologie-Santé - Spécialité Recherche Clinique et Santé Publique
1ère inscription en thèse :
Novembre 2017 /
5A these 2021
École doctorale :
Sciences de la Vie et de la Santé
Sujet :
Surmonter les défis qui font face aux thérapies géniques pour les maladies génétiques rares du système nerveux central (SNC): du développement à l'autorisation de mise sur le marché et la commercialisation
Directeur de thèse :
Mondher TOUMI
Co-directeur :
Clément FRANCOIS
Unité de recherche :
CEReSS - Centre dEtudes et de Recherche sur les Services de Santé et la Qualité de Vie
Intitulé de l'équipe :
Master
Intitulé : MSc International Relations
Septembre 2015 - London School of Economics
Langues vivantes
Arabe : C2 - Courant
Français : C1 - Avancé
Anglais : Maternel
Production scientifique
-
Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment.
Regulatory and Economic Aspects in Oncology Recent Results in Cancer Research
2019
Jaroslawski Szymon, Hanna Eve, Dabbous Monique, Chachoua Lylia, Toumi Mondher.
https://link.springer.com/chapter/10.1007/978-3-030-01207-6_4
-
President Trump's prescription to reduce drug prices: from the campaign trail to American Patients First.
Journal of Market Access and Health Policy
2019
Monique Dabbous, Clement Francois, Lylia Chachoua, Mondher Toumi
https://www.tandfonline.com/doi/full/10.1080/20016689.2019.1579597
-
Why American Patients First is likely to raise drug prices outside of the United States.
Journal of Market Access and Health Policy
2019
Monique Dabbous, Cyprien Milea, Steven Simoens, Clement Francois, Claude Dussart, Lylia Chachoua, Borissov Borislav, Mondher Toumi
https://www.tandfonline.com/doi/full/10.1080/20016689.2019.1650596
-
Managed Entry Agreements: Policy Analysis From the European Perspective
Value in Health
2020
Dabbous M., Chachoua L., Caban A., Toumi M
https://www.valueinhealthjournal.com/article/S1098-3015(20)30041-3/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301520300413%3Fshowall%3Dtrue
-
Joint Collaborations and future perspectives for gene therapies
Cell & Gene Therapy Insights
2020
Dabbous M., Borissov B., Dussart C., Toumi M., Hanna E
https://www.insights.bio/cell-and-gene-therapy-insights/journal/article/1720/Joint-collaborations-and-future-perspectives-for-gene-therapies
-
Health Technology Assessment of Gene Therapies in Europe and the USA: Analysis and Future Considerations
Cell & Gene Therapy Insights
2019
Qui T., Hanna E., Dabbous M., Borislav B., Toumi M.
https://insights.bio/cell-and-gene-therapy-insights/journal/article/115/Health-Technology-Assessment-of-Gene-Therapies-in-Europe-and-the-USA-Analysis-and-Future-Considerations
-
Regenerative Medicine Regulatory Policies: a Systematic Review and International Comparison
Health Policy
2020
Qiu T., Hanna E., Dabbous M., Borislav B., & Toumi M.
https://www.sciencedirect.com/science/article/abs/pii/S0168851020301032?via%3Dihub
-
The diversity in regenerative medicines regulations in Europe, USA and Japan
Cell & Gene Therapy Insights
2019
Qiu T., Dabbous M., Chachoua L., Dussart C., and Toumi, M
https://insights.bio/cell-and-gene-therapy-insights/journal/article/117/The-diversity-in-regenerative-medicines-regulations-in-Europe-USA-and-Japan
-
Amortization of Gene Replacement Therapies: A Health Policy Analysis Exploring a Mechanism for Mitigating Budget Impact of High-Cost Treatments
Health Policy
2021
Monique Dabbous, Mondher Toumi, Steven Simoens, Juergen Wasem, , Gauri Saal, Yitong Wang, José Luis Huerta Osuna,Clément François, Lieven Annemans, Johann-Matthias Graf von der Schulenburg, Oriol Sola-Morales, Daniel Malone,Louis P. Garrison
https://doi.org/10.1016/j.healthpol.2021.11.005
-
TRUMPS PLANS TO REDUCE DRUG PRICES- FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRST
ISPOR & Value in Health
2018
Dabbous M., Rémuzat C., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-europe-2018/trumps-plans-to-reduce-drug-prices-from-the-campaign-trail-to-american-patients-first
-
COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?
ISPOR & Value in Health
2018
Dabbous M., Rémuzat C., Dussart C., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-europe-2018/could-the-us-administration-impose-drug-price-raises-in-the-european-union-eu-
-
DOES DISEASE PREVALENCE HAVE AN IMPACT ON PRICE OF ORPHAN DRUGS IN EUROPE?
ISPOR & Value in Health
2018
Chachoua L., Hanna E., Achour L., Dabbous M., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-europe-2018/does-disease-prevalence-have-an-impact-on-price-of-orphan-drugs-in-europe-
-
ASSESSMENT OF HTA AND PRICE HETEROGENEITY OF ONCOLOGY PRODUCTS- A COMPARISON BETWEEN FRANCE AND GERMANY
ISPOR & Value in Health
2018
Dabbous M., Hanna E., Chachoua L., Dussart C., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/assessment-of-hta-and-price-heterogeneity-of-oncology-products-a-comparison-between-france-and-germany
-
INTERNATIONAL COMPARISON OF HTA DECISIONS FOR ONCOLOGY PRODUCTS
ISPOR & Value in Health
2018
Dabbous M., Achour L., Chachoua L., Hanna E., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/international-comparison-of-hta-decisions-for-oncology-products
-
HOW DOES G-BA DECISION IMPACT ONCOLOGY DRUG PRICES IN GERMANY?
ISPOR & Value in Health
2018
Chachoua L., Dabbous M., Achour L., Hanna E., Toumi M., Borissov BN.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/how-does-g-ba-decision-impact-oncology-drug-prices-in-germany-
-
EUROPEAN COLLABORATION FOR INNOVATIVE HIGH COST MEDICINES
ISPOR & Value in Health
2018
Achour L., Chachoua L., Dabbous M., Hanna E., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/european-collaboration-for-innovative-high-cost-medicines
-
ARE ORPHAN DRUG PRICES FAIR?
ISPOR & Value in Health
2018
Hanna E., Chachoua L., Dabbous M., Achour L., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/are-orphan-drug-prices-fair-
-
DOES DISEASE AREA HAVE AN IMPACT ON ORPHAN DRUG PRICES?
ISPOR & Value in Health
2018
Hanna E., Chachoua L., Dabbous M., Dussart C., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/does-disease-area-have-an-impact-on-orphan-drug-prices-
-
COMPARISON OF ORPHAN DRUGS PRICES- A EUROPEAN COMPARISON
ISPOR & Value in Health
2018
Hanna E., Chachoua L., Achour L., Dabbous M., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-asia-pacific-2018/comparison-of-orphan-drugs-prices-a-european-comparison
-
OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES- GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE
ISPOR & Value in Health
2019
Dabbous M., François C., Chachoua L., Hanna E., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3122/97743
-
THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING- A LITERATURE REVIEW
ISPOR & Value in Health
2019
Chachoua L., Germain N., Dabbous M., François C., Toumi M.
https://www.ispor.org/heor-resources/presentations-database/presentation/euro2019-3118/97221
-
Use of Patient Preference Information in Benefit-Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
Frontiers Medicine
2020
Chachoua L., Dabbous M., Francois C., Dussart C., Aballea S., Toumi M.
https://www.frontiersin.org/articles/10.3389/fmed.2020.543046/full
-
Chinese guidelines related to novel coronavirus pneumonia
Journal of Market Access and Health Policy
2020
Tingting Qiu, Shuyao Liang, Monique Dabbous, Yitong Wang, Ru Han, and Mondher Toumi
https://www.tandfonline.com/doi/full/10.1080/20016689.2020.1818446